KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Cash & Equivalents (2016 - 2025)

Exact Sciences has reported Cash & Equivalents over the past 16 years, most recently at $956.0 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 59.1% to $956.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $956.0 million through Dec 2025, up 59.1% year-over-year, with the annual reading at $956.0 million for FY2025, 59.1% up from the prior year.
  • Cash & Equivalents was $956.0 million for Q4 2025 at Exact Sciences, up from $789.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $1.1 billion in Q1 2021 and troughed at $11.7 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $392.5 million (2021), against an average of $466.7 million.
  • Year-over-year, Cash & Equivalents skyrocketed 183.18% in 2023 and then crashed 97.79% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $315.5 million in 2021, then fell by 23.13% to $242.5 million in 2022, then soared by 149.65% to $605.4 million in 2023, then fell by 0.74% to $600.9 million in 2024, then surged by 59.1% to $956.0 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Cash & Equivalents are $956.0 million (Q4 2025), $789.0 million (Q3 2025), and $11.7 million (Q2 2025).